These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23593209)

  • 1. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
    D'Addio F; Ueno T; Clarkson M; Zhu B; Vergani A; Freeman GJ; Sayegh MH; Ansari MJ; Fiorina P; Habicht A
    PLoS One; 2013; 8(4):e60391. PubMed ID: 23593209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
    Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
    Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo.
    Yamada A; Salama AD; Sho M; Najafian N; Ito T; Forman JP; Kewalramani R; Sandner S; Harada H; Clarkson MR; Mandelbrot DA; Sharpe AH; Oshima H; Yagita H; Chalasani G; Lakkis FG; Auchincloss H; Sayegh MH
    J Immunol; 2005 Feb; 174(3):1357-64. PubMed ID: 15661893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
    Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
    Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD27low natural killer cells prolong allograft survival in mice by controlling alloreactive CD8+ T cells in a T-bet-dependent manner.
    Lantow M; Eggenhofer E; Sabet-Baktach M; Renner P; Rovira J; Koehl GE; Schlitt HJ; Geissler EK; Kroemer A
    Transplantation; 2015 Feb; 99(2):391-9. PubMed ID: 25606781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.
    Williams MA; Trambley J; Ha J; Adams AB; Durham MM; Rees P; Cowan SR; Pearson TC; Larsen CP
    J Immunol; 2000 Dec; 165(12):6849-57. PubMed ID: 11120808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights in CD28-independent allograft rejection.
    Habicht A; Najafian N; Yagita H; Sayegh MH; Clarkson MR
    Am J Transplant; 2007 Aug; 7(8):1917-26. PubMed ID: 17617854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive.
    Zhai Y; Meng L; Busuttil RW; Sayegh MH; Kupiec-Weglinski JW
    J Immunol; 2003 Mar; 170(6):3024-8. PubMed ID: 12626556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD160 Stimulates CD8
    Tan CL; Peluso MJ; Drijvers JM; Mera CM; Grande SM; Brown KE; Godec J; Freeman GJ; Sharpe AH
    Immunohorizons; 2018 Aug; 2(7):238-250. PubMed ID: 31022694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts.
    Jones TR; Ha J; Williams MA; Adams AB; Durham MM; Rees PA; Cowan SR; Pearson TC; Larsen CP
    J Immunol; 2002 Feb; 168(3):1123-30. PubMed ID: 11801646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
    Giustiniani J; Marie-Cardine A; Bensussan A
    J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T cell priming and promotes Th type 2 responses to transplantation antigens.
    Coudert JD; Coureau C; Guéry JC
    J Immunol; 2002 Sep; 169(6):2979-87. PubMed ID: 12218112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.
    Nikolova M; Marie-Cardine A; Boumsell L; Bensussan A
    Int Immunol; 2002 May; 14(5):445-51. PubMed ID: 11978774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactive CD8 T-cell primed/memory responses and accelerated graft rejection in B-cell-deficient sensitized mice.
    Ji H; Shen XD; Gao F; Busuttil RW; Zhai Y; Kupiec-Weglinski JW
    Transplantation; 2011 May; 91(10):1075-81. PubMed ID: 21427633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of innate co-receptor TREM-1 signaling reduces CD4(+) T cell activation and prolongs cardiac allograft survival.
    Schiechl G; Brunner SM; Kesselring R; Martin M; Ruemmele P; Mack M; Hirt SW; Schlitt HJ; Geissler EK; Fichtner-Feigl S
    Am J Transplant; 2013 May; 13(5):1168-80. PubMed ID: 23463907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD160: a unique activating NK cell receptor.
    Le Bouteiller P; Tabiasco J; Polgar B; Kozma N; Giustiniani J; Siewiera J; Berrebi A; Aguerre-Girr M; Bensussan A; Jabrane-Ferrat N
    Immunol Lett; 2011 Aug; 138(2):93-6. PubMed ID: 21324341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo.
    Yuan X; Salama AD; Dong V; Schmitt I; Najafian N; Chandraker A; Akiba H; Yagita H; Sayegh MH
    J Immunol; 2003 Mar; 170(6):2949-55. PubMed ID: 12626546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.